

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>UBS Oncology Impact Fund L.P.</u> <hr/> (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET <hr/> (Street) CAMBRIDGE MA 02142 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 02/07/2019	3. Issuer Name and Ticker or Trading Symbol <u>Harpoon Therapeutics, Inc. [HARP]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <input type="checkbox"/>	5. If Amendment, Date of Original Filed (Month/Day/Year) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Preferred Stock	(1)	(1)	Common Stock	1,525,165	0.00 ⁽¹⁾	D ⁽²⁾⁽³⁾	
Series B Preferred Stock	(1)	(1)	Common Stock	1,578,755	0.00 ⁽¹⁾	D ⁽²⁾⁽³⁾	
Series C Preferred Stock	(1)	(1)	Common Stock	417,853	0.00 ⁽¹⁾	D ⁽²⁾⁽³⁾	
Common Stock Warrant (Right to Buy)	11/01/2016	11/01/2026	Common Stock	76,258	0.0492	D ⁽²⁾⁽³⁾	
Common Stock Warrant (Right to Buy)	01/10/2017	01/10/2027	Common Stock	50,838	0.0492	D ⁽²⁾⁽³⁾	

1. Name and Address of Reporting Person* <u>UBS Oncology Impact Fund L.P.</u> <hr/> (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET <hr/> (Street) CAMBRIDGE MA 02142 <hr/> (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person*		
MPM Oncology Impact Management GP LLC		
(Last)	(First)	(Middle)
C/O MPM CAPITAL 450 KENDALL STREET		
(Street)		
CAMBRIDGE	MA	02142
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
MPM Oncology Impact Management LP		
(Last)	(First)	(Middle)
C/O MPM ASSET MANAGEMENT 450 KENDALL STREET		
(Street)		
CAMBRIDGE	MA	02142
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
Oncology Impact Fund (Cayman) Management L.P.		
(Last)	(First)	(Middle)
C/O MPM CAPITAL 450 KENDALL STREET		
(Street)		
CAMBRIDGE	MA	02142
(City) (State) (Zip)		

Explanation of Responses:

1. All series of convertible preferred stock will automatically convert into the number of shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
2. The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing director of Oncology GP LLC.
3. The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Remarks:

[/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund \(Cayman\) Management L.P., the GP of UBS Oncology Impact Fund L.P](#) 02/07/2019

[/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC](#) 02/07/2019

[/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP](#) 02/07/2019

/s/ Ansbert Gadicke, managing
director of MPM Oncology
Impact Management GP LLC,
the general partner of MPM
Oncology Impact
Management LP, the general
partner of Oncology Impact
Fund (Cayman) Management
L.P.

02/07/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.